- Home
- BTAI vs NERV Comparison
BTAI vs NERV Comparison
Compare BTAI & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTAI
- NERV
- Stock Information
- Founded
- BTAI 2017
- NERV 2007
- Country
- BTAI United States
- NERV United States
- Employees
- BTAI N/A
- NERV N/A
- Industry
- BTAI Biotechnology: Pharmaceutical Preparations
- NERV Biotechnology: Pharmaceutical Preparations
- Sector
- BTAI Health Care
- NERV Health Care
- Exchange
- BTAI Nasdaq
- NERV Nasdaq
- Market Cap
- BTAI 10.7M
- NERV 12.4M
- IPO Year
- BTAI 2018
- NERV 2014
- Fundamental
- Price
- BTAI $1.46
- NERV $1.56
- Analyst Decision
- BTAI Buy
- NERV Hold
- Analyst Count
- BTAI 5
- NERV 1
- Target Price
- BTAI $42.60
- NERV $5.00
- AVG Volume (30 Days)
- BTAI 97.3K
- NERV 5.9K
- Earning Date
- BTAI 05-12-2025
- NERV 05-13-2025
- Dividend Yield
- BTAI N/A
- NERV N/A
- EPS Growth
- BTAI N/A
- NERV N/A
- EPS
- BTAI N/A
- NERV 0.82
- Revenue
- BTAI $1,852,000.00
- NERV N/A
- Revenue This Year
- BTAI $41.00
- NERV N/A
- Revenue Next Year
- BTAI $197.21
- NERV N/A
- P/E Ratio
- BTAI N/A
- NERV $1.88
- Revenue Growth
- BTAI 5.47
- NERV N/A
- 52 Week Low
- BTAI $1.29
- NERV $1.15
- 52 Week High
- BTAI $42.08
- NERV $3.69
- Technical
- Relative Strength Index (RSI)
- BTAI 37.90
- NERV 40.93
- Support Level
- BTAI $1.34
- NERV $1.58
- Resistance Level
- BTAI $1.64
- NERV $1.74
- Average True Range (ATR)
- BTAI 0.15
- NERV 0.06
- MACD
- BTAI -0.01
- NERV -0.01
- Stochastic Oscillator
- BTAI 16.56
- NERV 0.00
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.